Back to top
more

REGENXBIO (RGNX)

(Delayed Data from NSDQ)

$7.40 USD

7.40
344,201

+0.02 (0.27%)

Updated Dec 24, 2024 01:00 PM ET

After-Market: $7.39 -0.01 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.35%
2Buy18.11%
3Hold9.74%
4Sell5.34%
5Strong Sell2.80%
S&P50011.41%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Company Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

General Information

REGENXBIO Inc

9804 MEDICAL CENTER DRIVE

ROCKVILLE, MD 20850

Phone: 240-552-8181

Fax: NA

Web: http://www.regenxbio.com

Email: ir@regenxbio.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 9/30/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 2/25/2025

EPS Information

Current Quarter EPS Consensus Estimate -1.32
Current Year EPS Consensus Estimate -4.90
Estimated Long-Term EPS Growth Rate 36.90
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 2/25/2025

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 7.38
52 Week High 28.80
52 Week Low 7.15
Beta 1.24
20 Day Moving Average 1,707,910.75
Target Price Consensus 37.64

RGNX

% Price Change
4 Week -22.97
12 Week -29.65
YTD -58.89
% Price Change Relative to S&P 500
4 Week -22.79
12 Week -32.14
YTD -67.17
Share Information
Shares Outstanding (millions) 49.54
Market Capitalization (millions) 365.64
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year (Q0/Q-4) 17.02%
vs. Previous Quarter (Q0/Q-1) -11.43%
   
Sales Growth
vs. Previous Year (Q0/Q-4) -16.31%
vs. Previous Quarter (Q0/Q-1) 8.53%
   
Price Ratios
Price/Book 1.21
Price/Cash Flow NA
Price / Sales 4.34
ROE
9/30/24 -70.65
6/30/24 -68.21
3/31/24 -70.72
ROA
9/30/24 -41.68
6/30/24 -40.07
3/31/24 -41.30
Current Ratio
9/30/24 3.05
6/30/24 3.53
3/31/24 3.59
Quick Ratio
9/30/24 3.05
6/30/24 3.53
3/31/24 3.59
Operating Margin
9/30/24 -283.19
6/30/24 -270.74
3/31/24 -299.96
Net Margin
9/30/24 -283.19
6/30/24 -270.74
3/31/24 -299.96
Pre-Tax Margin
9/30/24 -283.37
6/30/24 -270.91
3/31/24 -300.14
Book Value
9/30/24 6.10
6/30/24 7.05
3/31/24 7.97
Inventory Turnover
9/30/24 NA
6/30/24 NA
3/31/24 NA
Debt-to-Equity
9/30/24 0.00
6/30/24 0.00
3/31/24 0.00
Debt to Capital
9/30/24 0.00
6/30/24 0.00
3/31/24 0.00